NeurologyLive® Friday 5 — November 28, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Insight the Future of Anti-Tau Drug Development for Alzheimer Disease

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

2: Advancing DM1 and DMD Care: Insights on DYNE-101 and DYNE-251 Development

Doug Kerr, MD, PhD, chief medical officer at Dyne Therapeutics, discusses the clinical development of DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy.

3: Evolving Approaches to Seronegative NMOSD in New Diagnostic Criteria: Álvaro Cobo-Calvo, MD, PhD

The neurologist at the Multiple Sclerosis Center of Catalonia talked about the challenges of defining seronegative in new diagnostic criteria for neuromyelitis optica spectrum disorder [WATCH TIME: 5 minutes]

4: NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndromee

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

5: Lessons from the PACIFIC-STROKE Phase 2 Trial

In episode 3 of a NeurologyLive Insights series, Mike Sharma, MD, reviews findings from the phase 2 PACIFIC-STROKE trial and explains how its results informed the design and dose selection for OCEANIC-STROKE.